secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001159036-23-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme guides FY2023 revenue $815M-$845M, >20% growth; Non-GAAP EPS $2.50-$2.65
--------------------------------------------------------------------------------

- FY2023 total revenue guidance $815M-$845M, >20% growth over expected 2022 record revenue >$655M.
- Royalty revenue guided $445M-$455M (>20% growth); EBITDA $415M-$440M (>30% growth).
- Non-GAAP diluted EPS guidance $2.50-$2.65; up to $150M share repurchases under $750M authorization.
- Anticipates two ENHANZE SC launches (efgartigimod, atezolizumab) and four Phase 3 data readouts in 2023.
- Completed Antares Pharma acquisition in 2022; expects continued strength in DARZALEX SC and Phesgo royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/0001159036-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/halo-20230110.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer